Personalizing Chemotherapy for Patients With Metastatic Breast Cancer

1
Personalizing Chemotherapy for Patients With
Metastatic Breast Cancer
2
Program Goal
3
Outline
4
Therapeutic Goals
5
Phase 3 Clinical Trials With Overall Survival as
an End Point
6
FDA Criteria for Approval of Oncology Drugs for
Metastatic Breast Cancer
7
Survival and FDA Approval of Oncology Drugs for
Metastatic Breast Cancer
8
Drug Approvals for Metastatic Breast Cancer
9
Toxicities Associated With Approved Therapies
10
Sources of Antitubulins
11
Tubulin and Microtubules
12
Function of Microtubules
13
Structure-Activity Relationship to Taxanes
14
Trials Comparing Agents With Paclitaxel 175 mg/m2
Every 3 Weeks
15
Role of Albumin in Nab-Paclitaxel
16
Phase 3 Trial Standard Paclitaxel vs
Nab-Paclitaxel
17
Phase 3 Trials of Capecitabine With or Without
Ixabepilone in Pretreated Advanced Breast Cancer
18
Results of Phase 3 Trials of Capecitabine With or
Without Ixabepilone
19
Toxicities in Phase 3 Trials of Capecitabine With
or Without Ixabepilone
20
Capecitabine With or Without Ixabepilone in
Triple-Negative MBC
21
E2100 Paclitaxel With or Without Bevacizumab as
First-Line Therapy in MBC
22
CALGB 40502 Trial Design
23
CALGB 40502 Progression-Free Survival By
Treatment Arm
24
Dose Modifications by Treatment
25
EMBRACE Trial Design
26
Patient Characteristics
27
Treatment of Physicians Choice Received
28
(No Transcript)
29
Progression-Free Survival
30
Grades 3 and 4 Adverse Events
31
Eribulin Study 301
32
Overall Survival
33
Overall Survival By Receptor Status
34
Cytotoxic Therapy for Metastatic Breast Cancer
Summary
35
Abbreviations
36
Abbreviations (cont)
37
References
38
References (cont)
39
References (cont)
40
References (cont)
41
References (cont)
42
References (cont)